About Us

DeNovaMed Inc. is at the forefront of pharmaceutical innovation, dedicated to the discovery and development of life-saving antibiotics. With a deep-seated mission to combat diabetic foot ulcers (DFUs) and the escalating crisis of drug-resistant bacterial infections, we stand as a beacon of hope for patients facing these daunting healthcare challenges.

At DeNovaMed, innovation is the heart of our operations. Our state-of-the-art computer-aided drug design capabilities have yielded multiple classes of antibacterial compounds. These are not only drug-like in their efficacy but are distinctively structured to deter the development of future resistance.

Our preclinical candidate, DNM0547, is a testament to our commitment to underappreciated medical needs. This compound shows great potential as a topical treatment for DFU—a complication of diabetes that is much more common than most people think: 35 – 50 million DFUs/yr globally! Meanwhile, DNM0904, an ACP synthase (AcpS) inhibitor with systemic administration potential, is being tested widely to establish its utility in a variety of infectious diseases, including against multi-drug-resistant Gram-positive infections.

DeNovaMed is not just about creating drugs; it’s about forging a legacy of enduring health solutions. We are relentless in our pursuit of excellence, unwavering in our commitment to science, and dedicated to improving the lives of those we serve.